Practical Challenges in the Management of Oral Anticoagulation

Steven R. Kayser, PharmD


Prog Cardiovasc Nurs. 2005;20(2):80-85. 

In This Article


The recent ruling by the US Food and Drug Administration not to approve ximelagatran(Exanta; AstraZeneca Pharmaceuticals LP, Wilmington, DE) has dimmed the hopes of many practitioners for an easier way to manage oral anticoagulation therapy. Warfarin (Coumadin, Bristol-Myers Squibb Company, New York, NY) consequently remains the only oral anticoagulant available in the United States, and despite its proven efficacy, there are a number of challenging management issues. Recognition of how to manage some of these most challenging aspects of therapy is important in assuring safe and effective therapy.[1,2]


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.